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1ABSTRACT
Sputum pentraxin 3 concentration as a marker of airway inflammation 
and remodeling in childhood asthma
Hee Seon Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Myung Hyun Sohn)
Pentraxin 3 (PTX3) is soluble pattern recognition receptor, and acute phase 
protein that has emerged as a new serological marker reflecting tissue 
inflammation and damage under diverse diseases. We determined whether 
sputum PTX3 levels are elevated in patients with childhood asthma. We also 
investigated the relationship between sputum PTX3 levels and airway 
inflammation, pulmonary function, and bronchial hyperresponsiveness in 
children. A total of 260 children (140 patients with asthma and 120 control 
subjects) were enrolled in this study. PTX3 levels were measured in sputum 
supernatants with ELISA. We performed spirometrys and methacholine 
challenge tests while measuring total eosinophil count, and serum levels of total 
IgE and ECP in all children. Sputum PTX3 concentration was significantly 
higher in children with asthma (mean ± SE, 1094.55 ± 224.65 pg/mL) than 
control subjects (mean ± SE, 177.36 ± 30.00 pg/mL, p < 0.001). Children with 
moderate-to-severe persistent asthma showed significantly higher sputum PTX3 
levels (median, 1190.63 pg/mL; IQR, 302.70 to 2619.84 pg/mL) than those with 
mild persistent asthma (median, 391.72 pg/mL; IQR, 73.77 to 1352.35 pg/mL, p 
= 0.044) and intermittent asthma (median, 188.15 pg/mL; IQR, 80.41 to 745.08 
pg/mL, p = 0.006). Positive significant correlations were found between sputum 
PTX3 and bronchodilator response (r = 0.25, p = 0.013). Sputum PTX3 levels 
negatively correlated with FEV1 (r = -0.30, p = 0.001), FEV1/FVC (r = -0.27, p 
= 0.002), FEF25-75 (r = -0.392, p < 0.001). Sputum PTX3 levels also showed 
significant negative correlation with post- bronchodilator (BD) FEV1 (r = -0.25, 
p < 0.001) and post-BD FEV1/FVC (r = -0.25, p < 0.001). Our results would
2support that PTX3 is involved in the pathogenesis of asthmatic airways. Sputum 
PTX3 could be a supportive marker reflecting asthmatic airway inflammation 
and remodeling in childhood asthma.
----------------------------------------------------------------------------------------
Key words : Pentraxin 3, induced sputum, asthma, children.
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I. INTRODUCTION
Asthma is the most common chronic airway inflammatory disorder in 
children, characterized by variable airflow obstruction, airway 
hyperresponsiveness (AHR), and bronchodilator reversibility. Asthma has come 
to be recognized as a major worldwide public health issue.1 In Korea, the 
prevalence of asthma in children has increased.2 Asthma have a complex 
background that may result from the interaction of various host and 
environmental factors, and numerous inflammatory cells and mediators have 
been found to be involved.1,3 However, the underlying pathogenesis of asthma 
has not yet been fully defined.
Pentraxin 3 (PTX3) is a member of the long pentraxins, a soluble pattern 
recognition receptor with non-redundant functions in inflammation and innate 
immunity.4,5 It is an acute phase protein secreted in response to toll-like receptor 
(TLR) activation or proinflammatory cytokines.6,7 Recently, PTX3 has been 
studied as an emerging marker reflecting tissue injury and inflammation6,8 under 
various pathological conditions such as acute respiratory distress syndrome,9
atherosclerosis,10 small-vessel vasculitis,11 rheumatoid arthritis,12 chronic kidney 
disease.13 PTX3 is produced by immune and structural cells in various 
tissues.5,6,14 Recently, it has been reported that airflow limitation are associated 
with lower pulmonary interstitial expression of PTX3 in chronic obstructive 
pulmonary disease (COPD).15 In asthma, the evidence was shown that PTX3 
expression is increased in allergic asthmatic airways.5 In addition, it has been 
4reported that sputum PTX3 levels were elevated in adult asthma16 and correlated 
with the airflow limitation of the asthma patients.17
We hypothesized that PTX3 could play an important role in childhood 
asthma, so we examined sputum PTX3 concentration in childhood asthma and 
its relationship with various asthma indices. The aim of this study was to 
determine whether PTX3 concentrations in induced sputum were increased in 
asthmatic children compared to healthy subjects. We also investigated the 
relationship between sputum PTX3 levels and asthmatic airway inflammation, 
bronchial hyperresponsiveness and reversibility, and pulmonary function in 
children.
II. MATERIALS AND METHODS
1. Subjects
A total of 260 children were enrolled in this study. Among the 260 children, 
140 were diagnosed with asthma in accordance with American Thoracic 
Society criteria.18 Current asthma was defined as recurrent wheezing or 
coughs in the absence of a cold in the preceding 12 months with a physician's 
diagnosis, and AHR upon methacholine challenge (PC20 ≤16 mg/ml) or at 
least 12% reversibility of forced expiratory volume in 1 s (FEV1) after 
inhalation of β2 agonist. Among the 140 asthma patients, 72 were diagnosed 
with intermittent asthma, 35 were mild persistent asthma and 31 were 
moderate-to-severe persistent asthma.19 At the time of enrollment, all the 
asthmatic children did not received a maintenance therapy. Children treated 
with systemic corticosteroids due to asthma exacerbation in the preceding 
month were excluded from the study. The control group consisted of 120 
children who had visited the hospital for general health workup or vaccination, 
and had no history of wheezing, recurrent or chronic diseases, infection in the 
preceding 2 weeks, or hyperresponsiveness to methacholine. Total serum 
immunoglobulin E (IgE) levels, peripheral blood eosinophil count, and 
eosinophil cationic protein (ECP) levels were determined at the initiation of 
the evaluations. A specific IgE test was performed with six allergens common 
in Korea: Dermatophagoides pteronyssinus, Dermatophagoides farina, egg 
whites, cow milk, German cockroach, and Alternaria alternata. Atopy was 
defined as more than 0.7 KUa/L specific IgE to more than one allergen, or 150 
IU/ml total IgE. Atopy was also defined as more than one positive skin test 
5result of 12 common aeroallergens, including two types of house dust mites, 
cat and dog epithelium, as well as mold and pollen allergens. This study was 
approved by the Institutional Review Board of Severance Hospital (Seoul, 
Korea). Written consent for participation was obtained from parents, with 
verbal assent from children.
2. Spirometry and methacholine challenge test
Spirometry (VIASYS Healthcare, Inc., Conshohocken, PA) was performed,
and flow-volume curves were obtained according to American Thoracic 
Society guidelines before and after bronchodilator (BD) inhalation.20 A 
methacholine challenge test was performed according to standardized 
procedures.21 Each child inhaled increasing concentrations of methacholine 
(0.075, 0.15, 0.31, 0.62, 1.25, 2.5, 5, 10, 25, and 50 mg/ml) nebulized by a 
dosimeter (MB3; Mefar, Brescia, Italy) until FEV1 reduced by 20% from a 
post-nebulized saline solution value. The bronchial response was expressed as 
a provocative concentration of methacholine causing a 20% fall in FEV1
(PC20; measured in milligrams per milliliter) and was calculated by linear 
interpolation of the log dose response curve.
3. Sputum induction and processing
Sputum induction and processing were performed as previously described 
by Yoshikawa et al.22 All children were instructed to wash their mouths 
thoroughly with water. They then inhaled a 3% saline solution nebulized in an 
ultrasonic nebulizer (NE-U12; Omron Co., Tokyo, Japan) at maximum output 
at room temperature. The children were encouraged to cough deeply at 3-min 
intervals thereafter. After sputum induction, spirometry was repeated. If FEV1
had fallen, the child was required to wait until it returned to baseline values. 
Sputum samples were kept at 4°C for no more than 2 hrs before further 
processing. A portion of the samples was diluted with a phosphate-buffered 
saline solution containing 10 mmol/L of dithiothreitol (WAKO Pure Chemical 
Industries Ltd, Osaka, Japan) for cell count and was gently vortexed at room 
temperature for 20 min. After centrifugation at 400g for 10 min, the cell pellet 
was resuspended. We performed a sputum viability determination with the 
trypan blue exclusion method to ensure adequate viability. Total cell counts 
were performed with a haemocytometer, and slides were prepared with 
cytospin (Cytospin3; Shandon, Tokyo, Japan) and stained with 
6May–Gru¨nwald–Giemsa stain) for differential cell counts. Differential cell 
counts were performed by two observers who were blind to clinical details 
and who counted 400 nonsquamous cells.
4. Measurement of blood eosinophils, serum total IgE and ECP, and sputum 
PTX3
Eosinophils were counted automatically (NE-8000 system; Sysmex; Kobe, 
Japan) in peripheral blood, while serum total IgE and ECP levels were 
measured (CAP system; Pharmacia-Upjohn; Uppsala, Sweden). Sputum PTX3 
was individually detected with enzyme-linked immunosorbent assay kits 
(R&D Systems; Minneapolis, MN) according to the instructions of the 
manufacturer. 
5. Statistical analysis
Numerical variables were expressed as the mean and standard error (SE). 
Normal distribution was determined by Kolmogorov-Smirnov test. Numerical 
parameters with nonnormal distribution were presented as median and 
interquartile range (IQR). Statistical comparison of values between groups 
was made by the Mann-Whitney U-test. The correlation between sputum 
PTX3 concentrations and numerical parameters (blood eosinophil count; 
serum total IgE and ECP levels; sputum eosinophil count; and lung function 
parameters) was determined using Spearman rank correlation test. All 
comparisons were made two-sided. A p value < 0.05 was considered 
statistically significant. Statistical software (SPSS, version 18.0; SPSS Inc; 
Chicago, IL) was used for all analyses.
III. RESULTS
1. Subject characteristics
The clinical characteristics of the study subjects are summarized in Table 1. 
There were no significant differences in age and gender between the groups. 
The percentage of children with atopy was significantly higher in asthma 
group than those in control group (P < 0.001). Pulmonary function parameters, 
including FEV1 (P < 0.001), percentage change in FEV1 after BD therapy (P < 
0.001), FEV1/FVC (P < 0.001), and forced expiratory flow midexpiratory 
phase (FEF25–75) [P < 0.001], showed significantly lower levels in children 
7with asthma than in control subjects. The percentage of eosinophils in induced 
sputum was significantly higher in children with asthma than in control 
subjects (P < 0.001). The blood eosinophil count, serum ECP, and serum total 
IgE levels were increased in children with asthma compared with those in 
control subjects (P < 0.001).
Table 1. Subject characteristics
Values are expressed as number (percentage), mean ± SD, or median 
(Interquatile range) *P < 0.001 compared to control subjects.
2. Comparison of sputum PTX3 levels between subject groups
As shown in Figure 1, sputum PTX3 concentration was significantly higher 
in children with asthma (mean ± SE, 1094.55 ± 224.65 pg/mL) than control 
subjects (mean ± SE, 177.36 ± 30.00 pg/mL, p < 0.001). Among the asthmatic 
children, children with atopic asthma showed significantly higher sputum 
PTX3 levels (median, 533.57 pg/mL; interquartile range [IQR], 96.28 to 
1345.87 pg/mL) than those with nonatopic asthma (median, 176.49 pg/mL; 
IQR, 61.64 to 561.97 pg/mL, p = 0.015)[Figure 2]. No significant differences 
were found between control group with atopy (median, 64.59 pg/mL; IQR, 
18.52 to 201.69 pg/mL) and without atopy (median, 50.70 pg/mL; IQR, 23.30 
to 304.36 pg/mL, p = 0.415).
Characteristics Asthma (n=140) Control (n=120)
Age, yr 8.1 (6.6-10.3) 9.3 (7.3-11.4)
Sex, M (%) 95 (66) 77 (61)
Atopy, with (%) 97 (69)* 56 (47)
FEV1, % pred 96.6  ± 16.5* 105.2 ± 12.2
Change in FEV1, % 7.2 ± 8.1* 2.3 ± 4.1
FEV1/FVC, % 84.4 ± 9.1* 89.1 ± 5.8
FEF25-75, % pred 78.7 ± 27.9* 99.1 ± 23.6
Total IgE, IU/mL 274 (104-684)* 113 (47-296)
Blood eosinophil, uL 370 (190-710)* 190 (110-350)
Serum ECP, ug/L 25.1 (13.7-44.2)* 17.0 (9.0-31.2)
Sputum eosinophil, % 4 (1-15)* 0 (0-1)
8Figure 1. Comparison of sputum PTX3 levels between 
groups. Asthmatic children had significantly higher levels of 
sputum PTX3 than the control subjects (P < .001).
Figure 2. Comparison of sputum PTX3 levels between 
atopic and nonatopic asthma groups. Children with atopic 
asthma had significantly higher levels of sputum PTX3 than 
those with nonatopic asthma (P = 0.015).
93. Sputum PTX3 levels of asthma severity groups
Comparison of sputum PTX3 levels among the asthma subgroups of severity 
was shown in figure 3. There were no significant differences in age and 
gender among the groups. Children with moderate-to-severe persistent asthma 
showed significantly higher sputum PTX3 levels (median, 1190.63 pg/mL; 
IQR, 302.70 to 2619.84 pg/mL) than those with mild persistent asthma 
(median, 391.72 pg/mL; IQR, 73.77 to 1352.35 pg/mL, p = 0.044) and 
intermittent asthma (median, 188.15 pg/mL; IQR, 80.41 to 745.08 pg/mL, p = 
0.006). However, the intermittent asthma group and mild persistent asthma 
groups showed no significant differences (p = 0.27).
Figure 3. Comparison of sputum PTX3 levels among 
asthma subgroups of severity. Children with 
moderate-to-severe persistent asthma showed significantly 
higher sputum PTX3 levels than those with mild persistent 
asthma (P = 0.044) and intermittent asthma (P = 0.006). The 
intermittent asthma group and mild persistent asthma groups 
were showed no significant difference (p = 0.27)
4. Relationship between sputum PTX3 and allergic inflammation
Serum total IgE were positively correlated with sputum PTX3 
concentrations (r = 0.16, p = 0.015)[Figure 4A]. Significant positive 
correlations were also found between sputum PTX3 levels and serum ECP (r 
= 0.16, p = 0.024)[Figure 4B], blood eosinophil count (r = 0.15, p = 
0.024)[Figure 4C], sputum eosinophil count (r = 0.30, p < 0.001)[Figure 4D].
10
Figure 4. Correlation of sputum PTX3 levels with serum total IgE, ECP, 
blood and sputum eosinophil. Serum total IgE were positively correlated 
with sputum PTX3 concentration (A). Significant positive correlations were 
also found between sputum PTX3 levels and serum ECP (B).
5. Correlation of sputum PTX3 levels with pulmonary function and BDR
Sputum PTX3 concentrations negatively correlated with FEV1 (r = -0.30, p 
= 0.001)[Figure 5A], FEV1/FVC (r = -0.27, p = 0.002)[Figure 5B], FEF25-75 (r 
= -0.392, p < 0.001)[Figure 5C]. Significant positive correlations were found 
between sputum PTX3 levels and BDR (r = 0.25, p = 0.013)[Figure 5D].
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Figure 5. Correlation of sputum PTX3 with pulmonary function and BDR.
Sputum PTX3 concentrations negatively correlated with FEV1 (A), FEV1/FVC 
(B), FEF25-75 (C). Significant positive correlations were found between sputum 
PTX3 levels and BDR (D). 
Figure 6. Correlation of sputum PTX3 levels with post-bronchodilator (BD) 
FEV1 and FEV1/FVC. Sputum PTX3 levels showed significant negative 
correlation with post-BD FEV1 (A) and post-BD FEV1/FVC (B).
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As shown in Figure 6, sputum PTX3 levels also showed significant negative 
correlation with post-BD FEV1 (r = -0.25, p < 0.001)[Figure 6A] and post-BD 
FEV1/FVC (r = -0.25, p < 0.001)[Figure 6B]. No significant correlation was 
observed between sputum PTX3 levels and PC20 in methacholine challenge test.
IV. DISCUSSION
PTX3, the ﬁrst long pentraxin discovered, is an acute phase protein expressed 
locally in response to a various inﬂammatory responses.7 PTX3 is involved in 
innate immunity, inﬂammatory response, and female fertility.23-25 Furthermore, it 
has been suggested to be one of the inﬂammatory mediators related to lung 
injury.14,26 However, very little is known about the expression of PTX3 and its 
role in asthma. Recently, it has been demonstrated that PTX3 immunoreactivity 
was increased in bronchial tissues of allergic asthmatics compared to healthy 
controls, and mainly localized in the smooth muscle bundle.5 The authors 
provided the first evidence that PTX3 expression is increased in asthmatic 
airways.5 In this study, we found that sputum PTX3 concentration was 
significantly elevated in asthmatic children compared to control subjects. Results 
of the present study correspond with that of earlier study. Furthermore, because 
bronchial biopsy is a comparatively invasive procedure, especially in children, 
we suggest sputum induction as an alternative method for the quantitation of 
PTX3 in this study.
Another finding in our study is the correlation between sputum PTX3 and 
allergic inflammation. Children with atopic asthma showed higher sputum 
PTX3 levels than those with nonatopic asthma. Serum total IgE was positively 
correlated with sputum PTX3 levels. It is well known that IgE-dependent mast 
cell activation plays an important role in allergic airway inflammation.27 It has 
been shown that there is a direct relationship between level of serum IgE and 
likelihood of wheeze and likelihood of reduced lung function.28 Furthermore, 
current study found a significant positive correlation of sputum PTX3 levels 
with ECP, blood and sputum eosinophils. This result indicate that PTX3 
involves in eosinophilic inflammation, one of the most important features in 
asthmatic airway. Previously it has been demonstrated that PTX3 enhanced 
CCL11/eotaxin-1 release in human airway smooth muscle cells (HASMC), 
chemokine that plays an important role in eosinophilic airway inflammation and 
remodeling.5,29,30 Therefore, we may support the previous finding that sputum 
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PTX3 may play an important role in airway inflammation of atopic asthma.
There are few previous studies that assessed the correlation between PTX3 
levels and lung function parameters. Recent report has been shown that sputum 
PTX3 levels correlated with the airflow limitation in 29 asthmatic adults.17 In 
COPD patients, PTX3 expression in induced sputum did not have any 
correlation with FEV1.
15 In current study, sputum PTX3 levels showed 
significant negative correlation with FEV1, FEV1/FVC, FEF25-75, and positive 
correlations were found significantly between sputum PTX3 and BDR. The 
correlation between sputum PTX3 and BDR was demonstrated for the first time 
in this study. Sputum PTX3 is associated with critical characteristics of 
asthmatic airways including airflow limitation and airway reversibility. Our 
results can support the findings of earlier studies that PTX3 plays an important 
role in the pathogenesis of asthma. 
Although asthma has been considered as a condition of reversible airflow 
obstruction, many asthmatic patients have evidence of residual airway 
obstruction.31 Subjects with mild asthma have pulmonary function that is 
relatively well preserved. On the other hand, children with more severe asthma 
appear to have persistent airflow obstruction and failure to respond to 
bronchodilator.32 In this study, children with more severe asthma showed higher 
sputum PTX3 concentration. Especially, patients with moderate-to-severe 
persistent asthma showed significantly higher PTX3 levels compared to those 
with intermittent and mild persistent asthma. Recent studies have suggested an 
association between disease severity and airway remodeling characterized as 
structural changes.32-36 Airway remodeling has been observed in bronchial 
biopsies of both adults and children with asthma.36 However, the invasiveness 
of these diagnostic procedures limits the use of these methods for clinical 
routine in most asthma patients, especially in children.37 Indirect methods to 
detect features of airway remodeling include evaluation of airway wall 
thickness by imaging studies, measurement of cytokine and cell profiles, or 
assessment of lung function.38 Loss of reversibility of airway obstruction is a 
typical feature of airway remodeling.38 Therefore, the low post-BD FEV1/FVC 
ratio is useful as a marker of airway remodeling.38 In this study, sputum PTX3 
concentrations were highly correlated with post-BD FEV1 and post-BD 
FEV1/FVC. PTX3 was previously shown to play an important role may play a 
role in tissue remodeling at sites of inﬂammation.39 Previous in vitro study5 has 
demonstrated that HASMC are one of the major sources of PTX3 in the airways. 
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It has been shown that PTX3 has the ability to inhibit FGF2-induced migration 
of HASMC at least in vitro and can upregulate CCL11/ eotaxin-1 release. So, it 
has been suggested that PTX3 may potentially contribute to airway 
inflammation and subsequent remodeling in allergic asthma.5 In the current 
study, it is suggested that sputum PTX3 would be one of the helpful biomarkers 
of airway remodeling. The reason why PTX3 is highly elevated in induced 
sputum of asthmatic children and correlated with lung function remains unclear, 
further studies will be required to confirm the roles of sputum PTX3 in asthma.
V. CONCLUSION
To our knowledge, this is the first study that evaluated PTX3 in induced 
sputum of children with asthma. Our results could support that PTX3 is 
involved in the pathogenesis of asthmatic airway. Sputum PTX3 would be a 
supportive biomarker reflecting asthmatic airway inflammation and remodeling 
in childhood asthma.
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ABSTRACT (IN KOREAN)
소아 천식에서 기도염증 및 기도재형성을 반영하는 지표로써
유도객담 내 pentraxin 3 농도의 의의
<지도교수 손명현>
연세대학교 대학원 의학과
이 희 선
Pentraxin 3 (PTX3)는 패턴인식수용체에 속하는 급성기 반응 단백의
일종이며, 조직의 손상 및 염증 반응을 나타내는 표지인자로서의
역할에 대한 연구가 최근 들어 활발해지고 있다. 본 연구에서 저자는
소아천식 환자들의 유도객담을 분석하여 PTX3의 농도가 증가되어
있는지를 확인하고자 하였다. 또한, 유도객담 내 PTX3 농도와 소아의
기도 염증 및 과민성, 폐기능 등과의 연관성을 확인하고자 하였다. 총
260명의 소아들을 대상으로 연구를 진행하였으며 이들 중 천식환자
140명, 대조군 120명이었다. 모든 대상 소아들에게 폐기능검사와
메타콜린 기관지유발검사를 시행하였으며, 혈액을 채취하여 총
호산구 수, 총 IgE 농도, 혈청 호산구 양이온 단백의 농도를
측정하였다. 유도객담 내 PTX3의 농도는 천식환자군이(mean ± SE, 
1094.55 ± 224.65 pg/mL) 대조군에 비해(177.36 ± 30.00 pg/mL, p < 0.001) 
유의하게 높은 수치를 나타내었다. 또한, 중등도 및 중증 지속성 천식
환아들이(median, 1190.63 pg/mL; IQR, 302.70 to 2619.84 pg/mL) 경증
지속성 천식과(median, 391.72 pg/mL; IQR, 73.77 to 1352.35 pg/mL, p = 
0.044) 간헐성 천식 환아들에 비해(median, 188.15 pg/mL; IQR, 80.41 to 
745.08 pg/mL, p = 0.006) 유의하게 높은 PTX3 농도를 보였다. 유도객담
내 PTX3 농도는 폐기능검사에서 기관지확장제 반응 결과와 유의한
양의 상관관계를 보였으며(r = 0.25, p = 0.013), FEV1 (r = -0.30, p = 0.001), 
FEV1/FVC (r = -0.27, p = 0.002), FEF25-75 (r = -0.392, p < 0.001)와는
유의하게 음의 상관관계를 나타내었다. 또한 기관지확장제 흡입 후
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FEV1 (r = -0.25, p < 0.001) 및 FEV1/FVC (r = -0.25, p < 0.001)와 역시
유의한 음의 상관관계를 보였다. 유도객담 내 PTX3의 농도는
소아천식에서 기도염증 및 기도재형성을 반영하는 지표로써 역할을
기대할 수 있을 것으로 생각된다.
----------------------------------------------------------------------------------------
핵심되는 말 : Pentraxin 3, 유도객담, 천식, 소아.
